<DOC>
	<DOC>NCT02726022</DOC>
	<brief_summary>Participants with Chronic Hepatitis C (CHC) and normal ALT, who have been under treatment with peginterferon alfa-2a and ribavirin for at least 4 weeks, will be enrolled into this non-interventional, open-label study. The primary aim is to evaluate quality of life according to the 36-Item Short-Form Health Survey (SF-36) questionnaire, modified for the Greek population.</brief_summary>
	<brief_title>A Quality of Life Study of Peginterferon-Alfa-2a Plus Ribavirin in Participants With Chronic Hepatitis C and Persistently Normal Alanine Transaminase (ALT) Levels</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Serological confirmation of chronic infection by antihepatitis C virus (HCV) assay HCV ribonucleic acid (RNA) positive CHC with normal transaminases Compensated liver disease Nonpregnant and willing to use two contraceptive methods (if fertile) At least 4 weeks of prior treatment with peginterferon alfa2a and ribavirin Pregnant or lactating women Coinfection with hepatitis A or B, or human immunodeficiency virus (HIV) History of seizures or depression History of autoimmune disease, severe heart or lung disease, or renal failure with reduced creatinine clearance Uncontrolled thyroid disease Severe retinopathy Leukopenia or thrombocytopenia Bleeding esophageal varices or other evidence of hepatic decompensation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>